Increased neutralization and IgG epitope identification after MVA-MERS-S booster vaccination against Middle East respiratory syndrome

Authors: Anahita Fathi,^{1,2,3a,4} Christine Dahlke,^{1,2,3a} Verena Krähling,^{3b,5} Alexandra Kupke,^{3b,5} Nisreen M. A. Okba,⁶ Matthijs P. Raadsen,⁶ Jasmin Heidepriem,⁷ Marcel A. Müller,^{3d,8} Grigori Paris,⁷ Susan Lassen,^{1,2,3a} Michael Klüver,^{3b,5} Asisa Volz,^{3c,10} Till Koch,^{2,3a,4} My L. Ly,^{1,2,3a} Monika Friedrich,^{1,2,3a} Robert Fux,^{3c,9} Alina Tscherne,^{3c,9} Georgia Kalodimou,^{3c,9} Stefan Schmiedel,^{3a,4} Victor M. Corman,^{3d,8} Thomas Hestekamp,^{3e} Christian Drosten,^{3d,8} Felix F. Loeffler,⁷ Bart L. Haagmans,⁶ Gerd Sutter,^{3c,9} Stephan Becker,^{3b,5} Marylyn M. Addo^{1,2,3a*}

***Corresponding author**

Affiliations:

¹University Medical Center Hamburg-Eppendorf, Institute for Infection Research and Vaccine Development (IIRVD); Hamburg, Germany.

²Bernhard-Nocht-Institute for Tropical Medicine, Department for Clinical Immunology of Infectious Diseases; Hamburg, Germany.

³German Center for Infection Research, ^apartner site Hamburg-Lübeck-Borstel-Riems, ^bpartner site Gießen-Marburg-Langen, ^cpartner site Munich, ^dpartner site Berlin, ^eTranslational Project Management Office; Braunschweig, Germany.

⁴University Medical Center Hamburg-Eppendorf, First Department of Medicine, Division of Infectious Diseases; Hamburg, Germany.

⁵Philipps University Marburg, Institute of Virology; Marburg, Germany.

⁶Erasmus Medical Center, Department of Viroscience; Rotterdam, the Netherlands.

⁷Max Planck Institute of Colloids and Interfaces, Department of Biomolecular Systems; Potsdam, Germany.

⁸Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute of Virology; Berlin, Germany.

⁹LMU University of Munich, Institute of Infectious Diseases and Zoonoses; Munich, Germany.

¹⁰University of Veterinary Medicine Hannover, Institute of Virology; Hannover, Germany.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

One Sentence Summary: A late booster vaccination with the vector vaccine MVA-MERS-S against MERS-CoV is safe and significantly increases humoral immunogenicity including responses to four IgG epitopes.

Keywords: MVA-MERS-S, MERS-CoV, Phase 1 clinical trial, coronavirus, vaccine, MVA, Modified Vaccinia virus Ankara, vector, booster, antibody, immunogenic epitope.

Abstract

Vaccine development is essential for pandemic preparedness. We previously conducted a Phase 1 clinical trial of the vector vaccine candidate MVA-MERS-S against the Middle East respiratory syndrome coronavirus (MERS-CoV), expressing its full spike glycoprotein (MERS-CoV-S), as a homologous two-dose regimen (Days 0 and 28). Here, we evaluate a third vaccination with MVA-MERS-S in a subgroup of trial participants one year after primary immunization. A booster vaccination with MVA-MERS-S is safe and well-tolerated. Both binding and neutralizing anti-MERS-CoV antibody titers increase substantially in all participants and exceed maximum titers observed after primary immunization more than 10-fold. We identify four immunogenic IgG epitopes, located in the receptor-binding domain (RBD, n=1) and the S2 subunit (n=3) of MERS-CoV-S. The level of baseline anti-human coronavirus antibody titers does not impact the generation of anti-MERS-CoV antibody responses. Our data support the rationale of a booster vaccination with MVA-MERS-S and encourage further investigation in larger trials.

INTRODUCTION

Emerging infections pose a major threat to public health. In recent years, outbreaks of severe acute respiratory syndrome (SARS), Ebola virus disease (EVD) and, currently, coronavirus disease 2019 (COVID-19) have been declared public health emergencies of international concern. In response, international organizations such as the World Health Organization (WHO) and the Coalition of Epidemic Preparedness Innovations (CEPI) have developed guidance for research and development to increase pandemic preparedness, and swift and effective vaccine development plays a central role. It includes two strategic elements: The advancement of vaccine platforms, which can serve as blueprints for vaccine candidates against newly emerging pathogens, as well as the development of vaccine candidates against diseases likely to cause future epidemics, defined as priority diseases by the WHO¹.

Viral vectors represent promising vaccine platforms. They comprise recombinant attenuated or replication-deficient viruses that express gene sequences of the pathogen of interest. Vector vaccines are being evaluated as vaccine candidates against various emerging pathogens²⁻⁴, and have received licensure as vaccines against EVD^{5,6} and COVID-19^{7,8}. Modified Vaccinia virus Ankara (MVA) is a well-established replication-deficient poxviral vector that does not integrate into host cell DNA⁹. Non-recombinant MVA has been licensed as a smallpox vaccine, and recombinant MVA has been studied as a vector vaccine candidate for multiple infectious disease and cancer indications¹⁰. It has been administered to over 120,000 individuals, including immunocompromised populations and children^{6,11} and has demonstrated a favorable safety profile^{9,12}. In addition, a recombinant MVA-based vaccine has been licensed as part of a heterologous vaccination regimen against EVD⁵.

MVA-MERS-S is a novel MVA-based vaccine candidate against the Middle East respiratory syndrome coronavirus (MERS-CoV) encoding its full spike glycoprotein (S). The coronaviruses' spike glycoprotein has been readily identified as a highly immunogenic viral structure that is the main target of most coronavirus vaccine candidates (i.e., vaccines against MERS-CoV, SARS-CoV-1 and SARS-CoV-2)^{13,14}.

Necessary for viral entry, it consists of the subunits S1 and S2, where S1 contains the functionally

relevant receptor-binding domain (RBD), which mediates host cell binding and attachment and S2, which mediates membrane fusion via its fusion glycoproteins and the transmembrane domain.

MERS-CoV, alongside SARS-CoV-1 and -2, belongs to the group of highly pathogenic beta-coronaviruses that have been identified as priority pathogens¹. Infection may lead to pneumonia and multi-organ failure, and is associated with a case-fatality rate of up to 35%¹⁵. Since its emergence in 2012, MERS-CoV has caused multiple outbreaks and has been exported into 27 countries. Apart from MVA-MERS-S, one DNA¹⁶ and one adenoviral vector vaccine candidate¹⁷ against MERS-CoV have completed Phase 1 trials. However, there is still no licensed vaccine or specific therapy available.

In 2017-2018, we conducted a single-center, open-label Phase 1 clinical trial of MVA-MERS-S in 23 healthy men and women aged 18-55 years (EudraCT No. 2014-003195-23, ClinicalTrials.gov Identifier NCT03615911)¹⁸. Participants received two injections of either 1×10^7 plaque-forming units (PFU; low dose: LD) or 1×10^8 PFU (high dose: HD) MVA-MERS-S in a homologous regimen on Days 0 and 28. Safety, tolerability and immunogenicity were evaluated until the end of the study on Day (D) 180. The regimen was well-tolerated; only transient reactogenicity was observed and no severe or serious adverse events (SAE) occurred. Both cellular and humoral immune responses were elicited after two vaccinations. Seroconversion occurred in 75% of LD and 100% of HD participants, peaked on D42, and binding antibody (Ab) titers correlated with neutralizing antibody (nAb) levels. However, it is not known whether booster vaccinations with MVA-MERS-S are necessary to induce optimal immunogenicity.

In this study, we examine the safety profile and the immunogenicity of a booster vaccination in a subgroup of the original MVA-MERS-S trial participants one year (12 ± 4 months) after primary immunization. We find that MVA-MERS-S booster vaccination is safe and substantially increases both MERS-CoV-specific binding and neutralizing antibody titers. MVA-MERS-S vaccination induces antibody responses to four S1 and S2 IgG epitopes, including one epitope previously described to be the target of an anti-MERS-CoV monoclonal antibody found in convalescent individuals that showed protective capacity in mice. The results presented here contribute to our understanding of the MVA-

MERS-S vaccine platform and support the further assessment of MVA-MERS-S booster vaccinations, which are currently evaluated in a larger Phase 1b trial (NCT04119440).

RESULTS

Study overview

A study overview is given in Fig. 1. Ten trial participants were recruited to receive a third vaccination (booster vaccination) with MVA-MERS-S one year (12 ± 4 months) after primary immunization. Three individuals had been primed with the LD and seven with the HD on Days 0 and 28. As the higher dose (1×10^8 PFU) of MVA-MERS-S had proven to be safe and immunogenic, all participants received this dose independent of initial LD/HD group. The booster vaccinations were administered between March 13th and 18th, 2019 (Boost Day 0; B:D0) and the participants returned to the study site for immunogenicity and/or safety assessments on B:D1, B:D3, B:D7 and B:D14. All participants completed the study on B:D28. Supplementary Table S1 provides an overview of participant characteristics. In addition, healthy unvaccinated individuals served as a control group for immunogenicity analyses ($n=2-6$, depending on the assay). Analyses on pre-existing immunity to other common-cold human coronaviruses (HCoV) were performed on all participants of the original Phase 1 MVA-MERS-S clinical trial.

Safety profile of the booster vaccination

Nine participants (90%) experienced at least one adverse event (AE) following the booster vaccination. In total, 51 AEs were recorded, of which 40 were classified as related and 11 as unrelated to the vaccine. The most common AE was local reactogenicity, experienced by 9/10 vaccinees, followed by fatigue/malaise (6/10 vaccinees). The majority of related AEs (80%, 32/40) were mild (grade 1) and solicited (92.5%, 37/40). Only one participant experienced grade 3 AEs one day after booster vaccination, all of which resolved spontaneously within 24 hours. No serious adverse events (SAEs) were recorded. AEs occurred early after vaccination (median 1 day, interquartile range (IQR) 0.25-1)

and were transient (median duration 1 day, IQR 0-2.75). A detailed overview of AE frequency and grade can be found in Supplementary Table S2.

As a result of the intensive study schedule, including early study visits and comprehensive laboratory analyses, we were able to closely assess hematologic changes and markers of organ function after booster vaccination. We observed transient changes in leukocyte counts with an increase by B:D1 and a decrease by B:D3 (Fig. 2a), which could be attributed to a respective dynamic in neutrophil counts (Fig. 2b). Thrombocyte counts transiently decreased by B:D1 (Fig. 2c). The changes of leukocyte, neutrophil and thrombocyte counts largely remained within the range of physiologic variation. A decrease in circulating lymphocytes on B:D1 (Fig. 2d) as well as a discreet increase in plasma C-reactive protein (CRP) levels on B:D1 and B:D3 (Fig. 2e) were also observed. None of these changes were clinically significant, however, they indicate biologic activity of the vaccination and suggest cellular redistribution to other compartments. By B:D7, no hematologic changes or CRP elevation were observed as compared to baseline. All other measured biomarkers remained unchanged (i.e., markers of renal, hepatic, pancreatic, and cardiac organ function/injury, and electrolytes).

Humoral immunogenicity of a late booster vaccination

We next assessed the effect of a booster vaccination with MVA-MERS-S on humoral immunogenicity, hypothesizing that it may enhance the magnitude of the MERS-specific immune response. Two distinct IgG ELISAs specific for the S1-subunit of MERS-CoV spike glycoprotein (MERS-CoV-S) were performed on B:D0, B:D7, B:D14 and B:D28, and included a control group of healthy, unvaccinated individuals with matching timepoints (Fig. 3). All individuals who received the booster vaccination had no detectable antibody titers on B:D0 prior to vaccination, as measured in both the in-house (Fig. 3a) and the EUROIMMUN (Fig. 3b) ELISAs (in-house ELISA optical density (OD) 0.08 [95% confidence interval (CI) 0.03 – 0.13], cut-off 0.5, all EUROIMMUN ELISA results see Supplemental Table S3). After booster vaccination antibody titers increased rapidly (by B:D7) and reached levels comparable to the

maximum titers observed after the initial two vaccinations (OD exemplary for the in-house ELISA: 1.05 [95% CI 0.76 – 1.44] on D42 vs. 1.01 [95% CI 0.66 – 1.54] on B:D7, $p=0.83$). By B:D14, titers further increased to significantly higher levels compared to D42 (OD exemplary for the in-house ELISA, Fig. 3a: 1.78 [95% CI 1.57 – 2.02] on B:D7, $p=0.004$) and remained high on B:D28 in both assays (OD exemplary for the in-house ELISA: 1.91 [95% CI 1.73 – 2.11]). All individuals (10/10) seroconverted by B:D14. No anti-MERS-CoV-S1 antibody titers were detected in the serum of the controls ($n=2$ in the in-house and $n=4$ in the EUROIMMUN ELISA, respectively).

Two neutralization assays, namely the virus neutralization tests (VNT) and the plaque reduction neutralization test assessing a $\geq 80\%$ reduction of plaques (PRNT₈₀), showed dynamics similar to the ELISA assays, in line with the strong correlation between binding and neutralizing MVA-MERS-S-induced anti-MERS-CoV-specific antibody responses that has previously been reported¹⁸. NAb levels increased early after booster vaccination and reached maximum levels by B:D14 and B:D28 in PRNT₈₀ (Fig. 4a) and VNT (Fig. 4b), respectively. These levels peaked earlier and exceeded the maximum levels observed after the initial vaccination regimen by more than ten-fold in both neutralization assays, specifically 11-fold in the PRNT₈₀ (reciprocal titer 49.2 [95% CI 30.8 – 78.8] on D35 vs. 520 [95% CI 346 – 782] on B:D14) and 12-fold in the VNT (reciprocal titer 5.10 [95% CI 1.74 – 14.9] on D42 vs. 60.7 [95% CI 39.0 – 94.3] on B:D28). Remarkably, all 5 participants who had not developed nAb levels above the threshold for positivity after the initial two vaccinations as measured by VNT had now developed positive nAb levels by B:D14 (Fig. 4c). Neutralizing antibodies against MERS-CoV were not detected in the serum of controls ($n=4$; Fig. 4a-b).

Characterization of immunogenic B cell epitopes

To further characterize antibody generation to MERS-CoV-S-specific linear epitopes, we used microarrays mapping the proteome of MERS-CoV-S. Sera of all ten booster dose recipients were screened for IgA, IgM and IgG with 15-mer peptides spanning the whole MERS-CoV-S protein (two aa

lateral shift, 670 peptides in total) on D0, D28, D42, B:D0 and B:D28. Figure 5 shows a schematic of MERS-CoV-S (Fig. 5A) with a heatmap of IgG binding to the individual MERS-CoV-S epitopes (Fig. 5b).

While we did not observe significant binding of IgA and IgM antibodies to MERS-CoV-S epitopes (data not shown), we identified a significant induction of antibody responses to four immunodominant IgG epitopes on B:D28 as compared to baseline, namely amino acid (AA) sequences 535-553, 887-913, 1,225-1,247 and 1,333-1,353 on MERS-CoV-S (Fig. 5c-f). For AA 535-553 (Fig. 5c), which consisted of three overlapping peptides (OLP), we observed a trend towards an increase of AA 535-553-specific IgG by D42 and a decline by B:D0, as well as a significant re-induction by B:D28 (Supplementary Fig. S1). Importantly, this epitope was located in the RBD of MERS-CoV-S (Fig. 5a). Epitope 887-913 (Fig. 5d), which contained five immunogenic OLP (peptides AA 893-907 and AA 895-909 were excluded due to low antibody binding on B:D28), was located in the S2 subunit of MERS-CoV-S adjacent to the S2' cleavage site. Epitopes 1,225-1,247 (Fig. 5e) and 1,333-1,353 (Fig. 4f), consisting of five and four OLP respectively, were both located in the stem helix of the S2 subunit, with epitope 1,333-1,353 being located within the transmembrane region. For both epitopes, we observed a significant increase in serum levels of epitope-specific antibodies as early as D28 after prime vaccination, a further increase by D42, followed by a decline by B:D0 and a strong re-induction by B:D28 (Supplementary Fig. S2).

Humoral cross-reactivity to other human coronaviruses

It has been observed that MERS-CoV infection leads to an increase of antibody titers against other common cold HCoV¹⁹ and MERS-CoV vaccine-induced cross-reactive antibodies to other HCoV have been described in a mouse model²⁰. To examine if prior exposition to other HCoV influences MVA-MERS-S-induced MERS-CoV-S-specific antibody generation, we assessed anti-S antibodies to HCoV-OC43, -229E, -HKU1, -NL63 (Fig. 6a-d) as well as MERS-CoV (Fig. 6e) and SARS-CoV-1 (Fig. 6f) using a CoV spike protein-based immunofluorescence assay (IFA). We screened all vaccinees who had received the initial vaccination regimen with vaccinations on Days 0 and 28 ($n=23$) and negative

controls ($n=6$) at baseline (D0) and 14 days after the second vaccination (D42). We did not find antibody reactivity against SARS-CoV-1 spike protein, which served as the control antigen. Likewise, anti-MERS-CoV-S antibodies were not detected in controls and in D0 specimen from vaccinees, but in contrast, were significantly increased in LD as well as HD vaccinees on D42. Anti-MERS-CoV-S immunofluorescence titers on D42 strongly correlated with nAb as measured in PRNT₈₀ (Supplementary Fig. S3). This observation was in line with previous data that showed a strong correlation of binding and neutralizing antibodies induced after MVA-MERS-S vaccination¹⁸, further cross-validating the individual assays. For the four common-cold HCoV, the majority of participants showed positive antibody titers at baseline (Supplementary Table S4). While the individual participants had variable titers, there was no correlation between baseline HCoV and anti-MERS-CoV-S titers on D42 (not shown) or fold-change of HCoV titers compared to MERS-CoV-S titers between pre (D0) and post vaccination (D42) timepoints (Supplementary Table S5).

DISCUSSION

We here investigated the safety and immunogenicity profile of an additional booster vaccination with the MVA-based vaccine candidate MVA-MERS-S against MEERS-CoV one year after primary immunization in a phase 1 clinical trial. Biologic monitoring demonstrated a good tolerability, and the reactogenicity of the booster vaccination appeared to be comparable to the initial primary immunization regimen¹⁸ with regard to dynamics, type, and severity of AE.

We found that a late homologous booster of MVA-MERS-S potentially increased insert-specific immunity. Anti-MERS-CoV-specific binding and neutralizing antibody titers increased in all participants, irrespective of initial LD or HD primary immunizations, and mean neutralizing antibody levels were up to 12-fold higher than the maximum levels observed after two vaccinations. Neutralizing antibodies were elicited in all individuals, even if they had previously failed to mount neutralizing antibodies following the original two-dose regimen. In a long-term follow-up of 7 individuals who received the booster vaccination we, furthermore, observed that MERS-CoV-specific antibody responses could still be detected 1.5 years after the third vaccination. Of note, we observed

that titers persistently exceeded the maximum titers observed after the initial two-vaccination regimen throughout the entire observation period (Weskamm et al., manuscript under review).

The licensed MVA vaccine against poxvirus is applied on Days 0 and 28. Consequently, this schedule has often been employed in the development of MVA-based vector vaccines²¹. Early secondary immunizations are chosen to maximize protective immunity in a timely manner, which is of particular importance in the context of outbreaks. However, additional and/or delayed booster vaccination may be required to increase the magnitude and duration of immunity and as a result, many established immunization regimens include a late booster vaccination in their regular schedule²².

Recently, the question of whether, when and how many booster vaccinations may be necessary for optimal protection has gained increased attention and has been a topic of intense debate in the context of SARS-CoV-2 vaccine development. Clinical trials and observational studies of booster vaccinations with distinct COVID-19 vaccines revealed acceptable safety profiles, which were comparable to those of primary immunization²³. Booster vaccinations against SARS-CoV-2, given at least 5 months after the primary series, increased immunogenicity and efficacy as well as the breadth of immune responses and level of cross-protection from symptomatic infection with variants^{24,25}. A COVID-19 booster vaccination also substantially increased immunogenicity in immunocompromised and elderly individuals, who are at an increased risk for severe disease and may not mount sufficient and/or durable anti-SARS-CoV-2 immunity after primary immunization^{26,27}. As a result, several national COVID-19 immunization guidances now recommend booster vaccinations 3-6 months after primary immunization^{28,29}.

With regard to MVA-vectored vaccines, previous studies likewise support the rationale of implementing a booster vaccination. In a clinical Phase 1/2a trial of an MVA-based H5N1 influenza vaccine, a booster vaccination one year after an initial 28-day prime-prime regimen markedly increased binding and neutralizing antibody titers³⁰. Booster vaccinations of MVA-vectored HIV vaccine candidates re-induced humoral and cellular insert-specific immunity when administered as late as 3-4 years after the last vaccination^{31,32}. Furthermore, a 56-day interval between vaccinations

led to an increased and more durable immune response compared to a 14-day interval in a non-human primate model of an MVA-based HIV vaccine, likely due to improved B-cell priming and innate immune responses³³. These data further support the rationale of implementing booster vaccinations in immunization regimens with MVA-based vaccine candidates.

The identification of immunogenic epitopes is another essential aspect for vaccine development and assessment, and the generation of a broad humoral immune response is desirable. While the RBD of MERS-CoV-S represents an important antigenic target to induce neutralizing antibodies³⁴, MERS-CoV-S epitopes outside the RBD contribute further to vaccine- or virus-induced humoral immunity. In mice, MERS-CoV vaccine candidates containing the whole spike protein have been shown to induce superior immunity to vaccine candidates containing the RBD only, and this was also demonstrated for vaccine protection capacity in non-human primates³⁵. Data from mice vaccinated with MVA-MERS-S show that the neutralizing capacity induced by the vaccine is only partially mediated by anti-RBD antibodies³⁶ and murine transfer studies of human monoclonal antibodies targeting non-RBD spike domains have demonstrated protection to lethal MERS-CoV challenge³⁷. In addition, the induction of humoral immunity to multiple RBD and non-RBD antigenic sites on the spike glycoprotein can defer the development of escape mutations³⁸.

In this study, we identified four immunogenic linear MERS-CoV-S IgG epitopes induced by vaccination with MVA-MERS-S. While epitope AA 535-553 is located in the immunogenic RBD, 3/4 epitopes were located in the S2 subunit. Epitope AA 887-913 lies within the S2' cleavage site, a conserved region shown to play a role in the induction of neutralizing antibodies in SARS-CoV-2 infection³⁹. We, furthermore, found two immunogenic epitopes, AA 1,333-1,353 and AA 1,225-1,247, located in the MERS-CoV-S stem helix. With regard to the latter, two human monoclonal anti-MERS-CoV antibodies (28D9 and 1.6C7) have recently been identified that both target a linear epitope in this location (AA 1229-1243)²⁰. These antibodies could not only be induced by MERS-CoV-S immunization of mice, but were also present in convalescent sera of humans and dromedary camels after natural infection with MERS-CoV. Moreover, they effectively neutralized MERS-CoV and showed protective capacity in

mice²⁰. These data suggest that antibodies targeting epitope AA 1,225-1,247 induced by MVA-MERS-S may also play an important role in vaccine-conferred immunity.

The S2 subunit is highly conserved among betacoronaviruses. Immune responses targeted towards epitopes conserved among different coronaviruses may confer cross-reactivity and could be of relevance in delivering cross-protection. A study assessing the prevalence of anti-SARS-CoV-2 antibodies in an unexposed population did detect anti-S2-specific SARS-CoV-2 antibodies – while not detecting RBD-specific responses – as well as a strong correlation of anti-HCoV-OC43 spike protein antibodies and anti-SARS-CoV-2 S2-antibodies in a COVID-19 convalescent cohort⁴⁰. The monoclonal anti-S2 directed antibodies 28D9 and 1.6C7 likewise showed cross-binding to other human betacoronaviruses, and in particular to HCoV-OC43²⁰. In this study, we aimed to understand whether prior exposure to HCoV had an influence on the magnitude of anti-whole MERS-CoV-S immune responses after vaccination with MVA-MERS-S. For the whole spike protein, however, we did neither find evidence that humoral immunity to HCoV influenced the generation of anti-MERS-CoV antibody responses, nor did we see cross-reactivity of HCoV antibodies to MERS-CoV and SARS-CoV-1.

Our results add valuable information for the advancement of MERS-CoV vaccine candidates and, more generally, the MVA vector vaccine platform, which is now also being assessed in the context of SARS-CoV-2 vaccine development. Recently, an MVA-vectored vaccine candidate expressing a pre-fusion stabilized SARS-CoV-2-S has been shown to efficiently induce binding and neutralizing antibodies and reduce viral replication after challenge in a non-human primate model⁴¹. A further vaccine candidate, MVA-SARS-2-S, expressing full-length SARS-CoV-2 spike glycoprotein (NCT04569383), demonstrated immunogenicity and protective capacity in a mouse model⁴² and we initiated a Phase 1b clinical trial of a modified vaccine construct based on the same platform, MVA-SARS-2-ST, expressing the pre-fusion-stabilized spike glycoprotein (NCT04895449) at our research site in July 2021.

We believe that the insights provided here lay the foundation for the further development of MVA-based vaccine candidates. However, this study has limitations. Resulting from an extension of the original Phase 1 trial of MVA-MERS-S, only a small and homogeneous group of healthy, Caucasian,

female individuals could be included. Additionally, due to constraints in the study design, the booster vaccination was given in a relatively wide time window (12±4 months). Concerning the assessment of immunogenic epitopes, we could, furthermore, not identify conformational or discontinuous B-cell epitopes since we were only able to assess linear epitopes via microarray. The findings can be interpreted as proof-of-concept and will need to be validated in future studies involving a bigger and more representative cohort.

The MVA-MERS-S vaccine candidate has now advanced to the next phase of clinical development and is currently assessed in a double-blind, two-center, randomized, placebo-controlled Phase 1b trial (NCT04119440) supported by CEPI. This ongoing study will build on our data by using a larger cohort to evaluate different dose levels, distinct prime-prime intervals (28 vs. 56 days) and, specifically, a third vaccination one year after prime.

MATERIALS AND METHODS

Study design and participants

As a follow-up to the initial Phase 1 clinical trial of MVA-MERS-S, where a two-dose vaccine regimen was administered on Days 0 and 28¹⁸, we designed a proof-of-concept study to assess the safety, tolerability and immunogenicity of an additional third vaccination of MVA-MERS-S as a booster dose 12±4 months after prime immunization. All study participants who had received both primary vaccinations (Days 0 and 28, $n=23$) were invited to participate in this follow-up study. The full amended study protocol including all inclusion and exclusion criteria is provided in the Supplementary Information.

In addition, healthy unvaccinated individuals were recruited into an observational study and donated blood samples, which served as controls for immunogenicity assays.

Study approval

The amendment to the clinical trial was reviewed and approved by the Competent National Authority (Paul-Ehrlich-Institute) and the Ethics Committee of the Hamburg Medical Association (reference number PVN5531). The trial was conducted as an investigator-initiated trial under the sponsorship of the University Medical Center Hamburg-Eppendorf (Hamburg, Germany) in accordance with ICH-GCP and is registered at ClinicalTrials.gov NCT03615911, EudraCT No. 2014-003195-23.

The observational study was registered with and approved by the Ethics Committee of the Hamburg Medical Association (reference number PV4780).

The clinical and observational studies were performed in accordance with the Declaration of Helsinki in its version of Fortaleza (2013). Written informed consent was obtained from all individuals prior to inclusion in the study.

Study procedures

Prior to booster vaccination (B:D0), baseline clinical parameters were recorded and blood for laboratory safety and immunogenicity analyses was collected. Participants were observed for 6 hours post vaccination to assess immediate vaccine reactions. They returned to the study site for study visits on B:D1, B:D3, B:D7, B:D14 and B:D28 (End of Study), on which blood samples for immunogenicity and/or safety assessments were drawn and AEs were evaluated.

Serum collection

Whole blood from vaccinees was drawn into serum gel-monovettes on B:D0 prior to vaccination, B:D7, B:D14 and B:D28, and the same procedure applied to unvaccinated individuals at matching timepoints. Serum monovettes were transported at room temperature and processed within 8 hours of blood collection. After centrifugation at 2500 x g, serum was aliquoted into cryotubes, immediately placed on dry ice and stored at -80°C until further usage.

Safety assessments

Safety was evaluated in accordance with the safety assessments of the initial two-vaccination regimen¹⁸. Solicited and unsolicited AE were classified on the basis of their severity (mild/moderate/severe), seriousness, relation to the vaccine (related vs. unrelated), and quality (local vs. systemic). Grading was performed by qualified study personnel according to the Common Terminology Criteria for Adverse Events (CTCAE), version 4.0 and the U.S. Food and Drug Administration (FDA) Voluntary Guidance 2007. AEs were classified as solicited if they occurred up to 14 days post vaccination and included local reactogenicity, gastrointestinal symptoms, fatigue/malaise, myalgia, arthralgia, headaches and fever/chills (see study protocol). Laboratory analyses included measurements of electrolytes, complete blood cell counts, creatinine, liver enzymes, C-reactive protein (CRP) and troponin levels. AE, clinical, and biologic monitoring were performed longitudinally (Fig. 1).

Binding anti-MERS-CoV-S1 antibody responses

Two IgG MERS-CoV-S1-specific ELISAs were performed by two independent laboratories as conducted in the initial MVA-MERS-S clinical trial¹⁸. A commercial ELISA (EUROIMMUN AG, Lübeck, order number EI 2604-9601 G) was performed according to the manufacturer's protocol and an in-house ELISA was performed according to the protocol published by Okba et al.⁴³. In both assays, OD was assessed at 450 nm, samples were measured in replicates of two, and their mean OD was calculated. For the EUROIMMUN ELISA, the cut off for positivity of each sample was calculated according to the manufacturer's instructions and a ratio of >1.1 (sample/calibrator) was considered positive. For the in-house ELISA, the cut off was set at an OD of 0.5, which was >6 standard deviations (SD) of the negative cohort used to establish the assay.

Anti-MERS-CoV neutralizing antibodies

Neutralizing anti-MERS-CoV antibodies were analyzed using a VNT and a PRNT, as previously described¹⁸. Briefly, the cytopathic effect (VNT) and plaque reduction of MERS-CoV-infected cells

(PRNT) were measured using HuH-7 cells incubated with MERS-CoV isolate EMC/2012 and serial dilutions of vaccinees' sera. For the VNT, the geometric mean titer of four replicates was calculated and a reciprocal titer of 8 was considered a positive response. In the PRNT, neutralization levels were defined as the reciprocal values of a $\geq 80\%$ reduction of plaques (PRNT₈₀) and a titer of ≥ 20 was considered positive (one measurement per sample).

Peptide microarrays

To assess antigenic peptides of MERS-CoV-S and identify B cell epitopes, we screened high-density peptide microarrays with sera of vaccinees using a protocol published by Heidepriem et al.⁴⁴. The whole proteome of MERS-CoV-S (GenBank ID: AFS88936.1) consisting of 1,353 AA was mapped as 670 15-mer peptides with a lateral shift of two aa as spot duplicates on a total of 55 peptide microarray replica, obtained from PEPperPRINT GmbH (Heidelberg, Germany). Briefly, 55 sera (10 vaccinees and 1 control with 5 timepoints) were diluted 1:200 and incubated on the arrays overnight. IgA, IgM and IgG serum antibody interactions were detected with Fc-specific differentially labeled fluorescent secondary antibodies, namely 0.5 mg/ml anti-human IgG-Fc fragment (cross-adsorbed) DyLight 680 (A80-304D6, Bethyl Laboratories, Montgomery, USA), 1.0 mg/ml anti-human IgM (mu chain) DyLight 549 (609-142-007, Rockland Immunochemicals Inc., Limerick, USA), 1.0 mg/ml anti-human IgA (alpha chain) antibody DyLight 800 (609-145-006, Rockland Immunochemicals Inc., Limerick, USA) and diluted in buffer (1:1,000 for both anti-human IgG and IgA, and 1:2,000 for anti-IgM). Antibody binding was measured in arbitrary fluorescence units (AFU), which were transformed with the inverse hyperbolic function (*area sinus hyperbolicus*) for statistical analysis. A mean transformed fluorescence intensity of >6 on B:D28 was considered significant binding. Epitope binding with mean values <6 AFU on B:D28 were considered unspecific binding and the epitope was, therefore, excluded from statistical analysis.

Differential HCoV and MERS-CoV IFA

Presence of antibodies to HCoV-OC43, HCoV-229E, HCoV-HKU1, HCoV-NL63 and MERS-CoV was evaluated by CoV spike protein-based recombinant IFAs, as previously described⁴⁵. SARS-CoV-1 spike protein was used as control antigen. Serial dilutions of vaccinee or control sera were evaluated, starting at a dilution of 1:40. A reciprocal titer of ≥ 40 was considered the cut-off for positivity. For statistical calculations and visualization, reciprocal titers < 40 were set at a value of 20.

Statistics

Descriptive statistics were used to summarize metric (number, mean with SD, minimum, maximum, and median with IQR) and categorical data (frequencies). Geometric means along with two-sided 95% CI were calculated using logarithmic transformations of OD values. To avoid overinterpretation of data, a non-normal distribution was assumed. Wilcoxon matched-pairs signed rank test and Mann-Whitney-U test were used to analyze paired and unpaired samples, respectively. Correlations were calculated using Spearman r . Statistical calculation of the p-value was two-sided and a p-value of ≤ 0.05 was considered statistically significant. Statistical analysis was performed using GraphPad Prism version 8.4.2. Figures were created with GraphPad Prism version 8.4.2 and BioRender.com.

DATA AVAILABILITY

All data associated with this study are in the manuscript or the Supplementary Information. Deidentified participant data collected during the trial can be shared through a data or materials transfer agreement. Requests from external researchers with respective research proposals should be sent to the corresponding author.

REFERENCES

- 1 World Health Organization. *Prioritizing diseases for research and development in emergency contexts*, <<https://www.who.int/activities/prioritizing-diseases-for-research-and-development-in-emergency-contexts>> (2021).
- 2 Fathi, A., Dahlke, C. & Addo, M. M. Recombinant vesicular stomatitis virus vector vaccines for WHO blueprint priority pathogens. *Hum Vaccin Immunother* **15**, 2269-2285, doi:10.1080/21645515.2019.1649532 (2019).
- 3 Ewer, K. et al. Chimpanzee adenoviral vectors as vaccines for outbreak pathogens. *Hum Vaccin Immunother* **13**, 3020-3032, doi:10.1080/21645515.2017.1383575 (2017).
- 4 Nagata, L. P., Irwin, C. R., Hu, W. G. & Evans, D. H. Vaccinia-based vaccines to biothreat and emerging viruses. *Biotechnol Genet Eng Rev* **34**, 107-121, doi:10.1080/02648725.2018.1471643 (2018).
- 5 Choi, M. J. et al. Use of Ebola Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020. *MMWR Recomm Rep* **70**, 1-12, doi:10.15585/mmwr.rr7001a1 (2021).
- 6 European Medicines Agency. *New vaccine for prevention of Ebola virus disease recommended for approval in the European Union*, <https://www.ema.europa.eu/en/documents/press-release/new-vaccine-prevention-ebola-virus-disease-recommended-approval-european-union_en.pdf> (2020).
- 7 European Medicines Agency, Committee for Medicinal Products for Human Use. *SmPC COVID-19 Vaccine AstraZeneca*, <https://www.ema.europa.eu/en/documents/product-information/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-product-information_en.pdf> (2021).
- 8 European Medicines Agency, Committee for Medicinal Products for Human Use. *SmPC COVID-19 vaccine (Ad26.COV2-S [recombinant])*

<https://www.ema.europa.eu/en/documents/product-information/covid-19-vaccine-janssen-epar-product-information_en.pdf> (2022).

- 9 Volkman, A. *et al.* The Brighton Collaboration standardized template for collection of key information for risk/benefit assessment of a Modified Vaccinia Ankara (MVA) vaccine platform. *Vaccine* **39**, 3067-3080, doi:10.1016/j.vaccine.2020.08.050 (2021).
- 10 Kreijtz, J. H., Gilbert, S. C. & Sutter, G. Poxvirus vectors. *Vaccine* **31**, 4217-4219, doi:10.1016/j.vaccine.2013.06.073 (2013).
- 11 Greenough, T. C. *et al.* Safety and immunogenicity of recombinant poxvirus HIV-1 vaccines in young adults on highly active antiretroviral therapy. *Vaccine* **26**, 6883-6893, doi:10.1016/j.vaccine.2008.09.084 (2008).
- 12 Mayr, A., Stickl, H., Muller, H. K., Danner, K. & Singer, H. [The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism (author's transl)]. *Zentralbl Bakteriell B* **167**, 375-390 (1978).
- 13 Krammer, F. SARS-CoV-2 vaccines in development. *Nature* **586**, 516-527, doi:10.1038/s41586-020-2798-3 (2020).
- 14 Mou, H. *et al.* The receptor binding domain of the new Middle East respiratory syndrome coronavirus maps to a 231-residue region in the spike protein that efficiently elicits neutralizing antibodies. *J Virol* **87**, 9379-9383, doi:10.1128/JVI.01277-13 (2013).
- 15 Shehata, M. M., Gomaa, M. R., Ali, M. A. & Kayali, G. Middle East respiratory syndrome coronavirus: a comprehensive review. *Front Med* **10**, 120-136, doi:10.1007/s11684-016-0430-6 (2016).
- 16 Modjarrad, K. *et al.* Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial. *Lancet Infect Dis* **19**, 1013-1022, doi:10.1016/S1473-3099(19)30266-X (2019).

- 17 Folegatti, P. M. *et al.* Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial. *Lancet Infect Dis* **20**, 816-826, doi:10.1016/S1473-3099(20)30160-2 (2020).
- 18 Koch, T. *et al.* Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial. *Lancet Infect Dis* **20**, 827-838, doi:10.1016/S1473-3099(20)30248-6 (2020).
- 19 Drosten, C. *et al.* Transmission of MERS-coronavirus in household contacts. *N Engl J Med* **371**, 828-835, doi:10.1056/NEJMoa1405858 (2014).
- 20 Wang, C. *et al.* A conserved immunogenic and vulnerable site on the coronavirus spike protein delineated by cross-reactive monoclonal antibodies. *Nat Commun* **12**, 1715, doi:10.1038/s41467-021-21968-w (2021).
- 21 European Medicines Agency. *SmPC Imvanex*, https://www.ema.europa.eu/en/documents/product-information/imvanex-epar-product-information_en.pdf (2018).
- 22 National Center for Immunization and Respiratory Diseases. General recommendations on immunization --- recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recomm Rep* **60**, 1-64 (2011).
- 23 Atmar, R. L. *et al.* Homologous and Heterologous Covid-19 Booster Vaccinations. *N Engl J Med*, doi:10.1056/NEJMoa2116414 (2022).
- 24 Falsey, A. R. *et al.* SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3. *N Engl J Med* **385**, 1627-1629, doi:10.1056/NEJMc2113468 (2021).
- 25 Arbel, R. *et al.* BNT162b2 Vaccine Booster and Mortality Due to Covid-19. *N Engl J Med* **385**, 2413-2420, doi:10.1056/NEJMoa2115624 (2021).
- 26 Hall, V. G. *et al.* Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients. *N Engl J Med* **385**, 1244-1246, doi:10.1056/NEJMc2111462 (2021).

- 27 Bar-On, Y. M. *et al.* Protection against Covid-19 by BNT162b2 Booster across Age Groups. *N Engl J Med* **385**, 2421-2430, doi:10.1056/NEJMoa2115926 (2021).
- 28 Robert Koch Institut. Beschluss der STIKO zur 16. Aktualisierung der COVID-19-Impfempfehlung. *Epidemiologisches Bulletin* **2**, 3-15 (2022).
- 29 Mbaeyi, S. *et al.* The Advisory Committee on Immunization Practices' Interim Recommendations for Additional Primary and Booster Doses of COVID-19 Vaccines - United States, 2021. *MMWR Morb Mortal Wkly Rep* **70**, 1545-1552, doi:10.15585/mmwr.mm7044e2 (2021).
- 30 Kreijtz, J. H. *et al.* Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1/2a clinical trial. *Lancet Infect Dis* **14**, 1196-1207, doi:10.1016/S1473-3099(14)70963-6 (2014).
- 31 Guardo, A. C. *et al.* Safety and vaccine-induced HIV-1 immune responses in healthy volunteers following a late MVA-B boost 4 years after the last immunization. *PLoS One* **12**, e0186602, doi:10.1371/journal.pone.0186602 (2017).
- 32 Nilsson, C. *et al.* Broad and potent cellular and humoral immune responses after a second late HIV-modified vaccinia virus ankara vaccination in HIV-DNA-primed and HIV-modified vaccinia virus Ankara-boosted Swedish vaccinees. *AIDS Res Hum Retroviruses* **30**, 299-311, doi:10.1089/aid.2013.0149 (2014).
- 33 Palgen, J. L. *et al.* Innate and secondary humoral responses are improved by increasing the time between MVA vaccine immunizations. *NPJ Vaccines* **5**, 24, doi:10.1038/s41541-020-0175-8 (2020).
- 34 Ying, T. *et al.* Exceptionally potent neutralization of Middle East respiratory syndrome coronavirus by human monoclonal antibodies. *J Virol* **88**, 7796-7805, doi:10.1128/JVI.00912-14 (2014).
- 35 Wang, L. *et al.* Evaluation of candidate vaccine approaches for MERS-CoV. *Nat Commun* **6**, 7712, doi:10.1038/ncomms8712 (2015).

- 36 Song, F. *et al.* Middle East respiratory syndrome coronavirus spike protein delivered by modified vaccinia virus Ankara efficiently induces virus-neutralizing antibodies. *J Virol* **87**, 11950-11954, doi:10.1128/JVI.01672-13 (2013).
- 37 Widjaja, I. *et al.* Towards a solution to MERS: protective human monoclonal antibodies targeting different domains and functions of the MERS-coronavirus spike glycoprotein. *Emerg Microbes Infect* **8**, 516-530, doi:10.1080/22221751.2019.1597644 (2019).
- 38 Wang, L. *et al.* Importance of Neutralizing Monoclonal Antibodies Targeting Multiple Antigenic Sites on the Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein To Avoid Neutralization Escape. *J Virol* **92**, doi:10.1128/jvi.02002-17 (2018).
- 39 Poh, C. M. *et al.* Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patients. *Nat Commun* **11**, 2806, doi:10.1038/s41467-020-16638-2 (2020).
- 40 Nguyen-Contant, P. *et al.* S Protein-Reactive IgG and Memory B Cell Production after Human SARS-CoV-2 Infection Includes Broad Reactivity to the S2 Subunit. *mBio* **11**, doi:10.1128/mBio.01991-20 (2020).
- 41 Routhu, N. K. *et al.* A modified vaccinia Ankara vector-based vaccine protects macaques from SARS-CoV-2 infection, immune pathology, and dysfunction in the lungs. *Immunity* **54**, 542-556.e549, doi:10.1016/j.immuni.2021.02.001 (2021).
- 42 Tscherne, A. *et al.* Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination. *Proc Natl Acad Sci U S A* **118**, doi:10.1073/pnas.2026207118 (2021).
- 43 Okba, N. M. A. *et al.* Sensitive and Specific Detection of Low-Level Antibody Responses in Mild Middle East Respiratory Syndrome Coronavirus Infections. *Emerg Infect Dis* **25**, 1868-1877, doi:10.3201/eid2510.190051 (2019).

- 44 Heidepriem, J. *et al.* Longitudinal Development of Antibody Responses in COVID-19 Patients of Different Severity with ELISA, Peptide, and Glycan Arrays: An Immunological Case Series. *Pathogens* **10**, doi:10.3390/pathogens10040438 (2021).
- 45 Corman, V. M. *et al.* Assays for laboratory confirmation of novel human coronavirus (hCoV-EMC) infections. *Euro Surveill* **17**, doi:10.2807/ese.17.49.20334-en (2012).

ACKNOWLEDGEMENTS

We thank all study volunteers without whom this study would not have been possible. We thank Dr. Saskia Borregaard, Dr. Alen Jambrecina and Laura Kaltenberg at the CTC North GmbH & Co. KG in Hamburg, Germany for regulatory support in submitting the study documents and for the operative management of the study conduct, as well as Elisabeth Möncke-Buchner and Petra Mackeldanz (both Charité-Universitätsmedizin Berlin, Institute of Virology) for excellent technical assistance. We are also grateful for the critical reading of the manuscript and the valuable advice provided by Dr. Sibylle Mellinghoff (Cologne University Hospital, Division of Infectious Diseases) and Elaine Hussey (University Medical Center Hamburg-Eppendorf, First Department of Medicine).

This research was supported by the German Center for Infection Research (DZIF), grant numbers FKZ8009801908, FKZ8009701702, FKZ8033801809 (section emergency vaccines) and FKZ8033701711 (infrastructure animal facility). AF received a DZIF Clinical Leave Grant, grant number FKZ80095CLANF. CDr was supported by the German Ministry of Research and Education (BMBF) BMBF-RAPID 01KI1723A. VMC was supported by BMBF project VARIPath (01KI2021). FFL was supported by the German Federal Ministry of Education and Research grant 13XP5050A and the MPG-FhG cooperation grant Glyco3Display. BLH is inventor on a MERS patent with Erasmus MC Rotterdam (No. WO2014045254 A3, no payments to author or institution). The funder of this publicly-funded investigator-initiated trial had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.

AUTHOR CONTRIBUTIONS

- Conceptualisation: MMA, SB, TH, GS
- Methodology & Supervision: MMA, SB, CDr, BLH, FFL, GS

- Investigation: VMC, CD, AF, RF, MF, JH, GK, MK, VK, AK, SL, MLL, MAM, NMAO, GP, MPR, AT, AV
- Study conduct: MMA, AF, TK, SS
- Formal analysis: CD, AF, MK, VK, AK, SL, FFL, MAM, NMAO, AV
- Writing – original draft: AF
- Writing – review and editing: MMA, CD, BLH, TH, GK, TK, VK, FFL, MAM, GS, AV
- Visualization: CD, AF, SL, FFL
- Project administration: MMA, CD, AF

COMPETING INTERESTS STATEMENT

The authors declare no competing interests.

FIGURES

Fig. 1. Study design and trial profile.

23 individuals completed a homologous primary immunization with two vaccinations (D0 and D28) of either 1x10⁷ PFU (LD, blue) or 1x10⁸ PFU MVA-MERS-S (HD, red), and were followed-up for 180 days (D), which concluded this part of the study (End of Study). Participants were invited to return for an additional third vaccination as a booster 1 year $\pm$ 4 months after prime. 10 participants (3 from the LD, 7 from the HD group) were re-enrolled and received a dose of 1x10⁸ PFU MVA-MERS-S. Safety and tolerability were assessed on boost (B) days (B:D) B:D0 (baseline), B:D1, B:D3 (not depicted), B:D7, B:D14, and B:D28; humoral immunogenicity was assessed on B:D0, B:D7, B:D14 and B:D28 (End of Study). All 10 participants completed the extension trial and were included in the analyses.

Fig. 2. Biologic monitoring.

Graphs represent changes in **(a)** leukocyte, **(b)** neutrophil, **(c)** thrombocyte, and **(d)** lymphocyte counts, as well as **(e)** C-reactive protein (CRP) levels, after booster vaccination. We observed an increase in leukocyte and neutrophil counts as well as CRP levels and a decrease in lymphocyte and thrombocyte counts on B:D1 compared to B:D0. These changes from baseline were transient and not clinically significant, but indicate biologic activity after vaccination. Boxes indicate 25-75 percentile; whiskers are min. to max.; medians are shown as horizontal lines within the boxes. ULN= upper limit of normal. LLN=lower limit of normal. * $p < 0.05$, ** $p < 0.005$, differences assessed using Wilcoxon matched-pairs signed rank test.

Fig. 3. Increase in anti-MERS-CoV-S-specific binding antibodies after booster vaccination.

Anti-MERS-CoV-S-specific binding antibodies were measured by two distinct ELISAs ((a) In-house ELISA, (b) EUROIMMUN ELISA). Antibody levels are measured in optical density values (y axes) at multiple timepoints after first (0, 35, 42, 84, 180) and booster (B:D0, B:D7, B:D14, B:D28) vaccinations (x-axes). Boxes indicate 25-75 percentile; whiskers are min. to max.; medians are shown as horizontal lines within the boxes. Arrows indicate vaccinations. Participants initially vaccinated with the LD are depicted in blue, former HD vaccinees are depicted in red, controls in grey. The horizontal dashed line in (a) indicates the cut-off level for positivity.

Fig. 4. Increase in MERS-CoV neutralizing antibodies after booster vaccination.

MERS-CoV neutralization was measured by (a) PRNT₈₀ and (b, c) VNT. Neutralizing antibody levels were measured in reciprocal titers (y axes) at multiple timepoints after first (Day 0, 35, 42, 84, 180) and booster vaccination (B:D0, B:D7, B:D14, B:D28) vaccinations (x-axes). Arrows indicate vaccinations. Horizontal dashed lines indicate the cut-off levels for positivity. (a)+(b) Boxes indicate 25-75 percentile; whiskers are min. to max.; medians are shown as horizontal lines within the boxes. Former LD and HD vaccinees are depicted in blue and red, respectively, controls in grey. (c) VNT titers after prime vaccination measured longitudinally in the 5 individuals who did not develop nAb after prime vaccinations.

Fig. 5. Identification of four immunogenic MERS-CoV-S epitopes.

(A) Schematic representation of the MERS-CoV-S protein. The N-terminal domain (NTD), receptor-binding domain (RBD), S1/S2 cleavage site (S1/S2), fusion peptide (FP), S2' cleavage site (S2'), heptad repeat 1 and 2 (HR1, HR2), transmembrane domain (TM) and cytoplasmic domain (CD) as well as the respective positions of the immunogenic epitopes are illustrated. **(B)** Microarray of 15-mer peptides spanning the complete MERS-CoV-S protein with a 13 AA overlap. Immunogenic B-cell peptides are marked with red lines. **(C-F)** IgG binding to the respective peptides on MERS-CoV-S was measured in fluorescence intensity (AFU) and is depicted as transformed values (areas sinus hyperbolicus, y axis). Mean levels of peptide-binding IgG at baseline (D0, white boxes) and 28 days after booster vaccination (B:D28, grey boxes) were compared using Wilcoxon matched-pairs signed rank test and are depicted for each peptide (x-axis) within the immunogenic epitopes **(C)** AA 535-553, **(D)** AA 887-913, **(E)** AA 1,225-1,247 and **(F)** AA 1,333-1,353. Boxes indicate 25-75 percentile; whiskers are min. to max.; medians are shown as horizontal lines within the boxes. *p<0.05, **p<0.005.

Fig. 6. Immunity to endemic HCoV compared to anti-MERS-CoV immunity.

Reciprocal anti-CoV spike protein antibody titers of (a) HCoV-OC43, (b) HCoV-229E, (c) HCoV-HKU1, (d) HCoV-NL63, (e) MERS-CoV, and (f) SARS-CoV (used as control antigen) were measured on D0 (pre-vaccination) and D42 via IFA. LD and HD vaccinees are depicted in blue and red, respectively, unvaccinated controls in grey. A titer of <40 (dotted line) was considered negative. While we observed increased anti-MERS-CoV titers on day 42 compared to baseline, there was no significant increase of anti-HCoV titers. ***p<0.001, assessed via Wilcoxon matched-pairs signed rank test.